Sign up Australia
Proactive Investors - Run By Investors For Investors

Patrys secures $3.5 million for anti-cancer therapies

The single tranche placement will see new shares issued priced at 3.4 cents.
sign saying funding
The capital raising was oversubscribed by investors

Patrys Ltd (ASX:PAB) has received firm commitments from institutional and sophisticated investors to raise $3.5 million through a share placement priced at 3.4 cents.

Funds raised will be used to accelerate the development of Patrys’ Deoxymab platform, which was licensed from Yale University in March 2016.

Patrys has established a strong position in the field of DNA damage repair (DDR) therapeutics with a novel approach that utilizes cell-penetrating antibodies to selectively kill cancer cells.

The company also has a range of new pre‐clinical studies planned to create shareholder value by supporting business development efforts.

Developing anti‐cancer therapies based on the Deoxymab platform

Patrys’ CEO and managing director Dr James Campbell said: “Patrys is pleased to announce that this over‐subscribed share placement attracted strong demand from institutional investors.

“We believe this result is indicative of strong investor interest in our efforts to develop anti‐cancer therapies based on the Deoxymab platform, which has created a novel position in the field of DNA damage repair antibody therapeutics.”

View full PAB profile View Profile

Patrys Timeline

January 11 2018

Related Articles

newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
man on a ventilator
January 25 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use